Articles On Orthocell (ASX:OCC)

Summary The ASX 200 breached 7,400 level for the first time to hit a fresh high of 7,406.20. The index closed 6.70 points higher at 7,386.20 ahead of the US Fed meeting scheduled tonight. The widely anticipated US Fed policy statement...

The patents cover the method of using CelGro® to repair a defect in soft tissue, such as tendons, ligaments and nerves, avoiding the use of damaging sutures.

The Orthocell Ltd (ASX: OCC) share price is climbing today. At the time of writing, it’s at 57.5 cents, up by 1.77%, settling back after jumping 4% in early trading. Let’s have a look at the latest announcement from the regenerative medici...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

A recent article published in the Advance Science magazine discussed research by Monash University that uncovered a new technique to alter the shape of individual stem cells, which could potentially speed up recovery times for bone replacem...

Regenerative medicine company Orthocell (ASX:OCC) has announced Chinese and Hong Kong patents have been granted for its novel CelGro collagen rope device, to augment the surgical repair of anterior cruciate ligament injuries.

China and Hong Kong have granted patents to the product, which is used to augment ligament repair surgeries.

China and Hong Kong have granted patents to the product, which is used to augment ligament repair surgeries.

Orthocell is well-positioned to establish CelGro® as the best-in-class membrane for bone and soft tissue repair and to realise multiple commercial partnering opportunities.

Regenerative medicine company Orthocell (ASX:OCC) has announced what it describes as positive results from the US animal pilot study of its CelGro in nerve regeneration compared to the current market-leading device.

Summary Regenerative medicine player Orthocell has announced positive results from the US 510(k) animal pilot study of CelGro®. AnteoTech has obtained firm commitments to raise AU$12M to accelerate its test product pipeline. Althou...

The breakthrough results position CelGro® as the potential market leader in nerve regeneration and restoration of voluntary muscle control in patients with tetraplegia or paralysed upper limbs with a strategic evaluation of medical device U...

The Orthocell Ltd (ASX: OCC) share price is rising today following news of a successful pilot animal study. The company states that as a result of the study, it’s seeking to fast-track US approval for its CelGro product. The Orthocell shar...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Regenerative medicine company Orthocell (ASX:OCC) has announced it has received notification from the Australian Department of Health that its CelGro Dental has been included on the Prostheses List.

Source:Phongphan ,Shutterstock ASX 200 has held its gains in the afternoon today. Australian bond yields are tracking lower today, while information technology sector is also lower. Australian markets are trading higher today. Most of th...

The Orthocell Ltd (ASX: OCC) share price is edging higher today following the inclusion of CelGro Dental on the Australian Prostheses List. When news broke out, the regenerative medicine company’s shares raced higher to 54 cents, before ea...

Source: Voronin76,Shutterstock Summary World-leading regenerative medicine company Orthocell revealed that CelGro® Dental was included on the Australian Prostheses List. Additional antiviral testing proved that Starpharma’s antiviral...

The prostheses list defines the minimum value of benefit private insurers pay for CelGro® Dental used in approved dental bone and soft tissue repair procedures.

Source: Guschenkova, Shutterstock Summary Amid the detrimental impact of the ongoing pandemic, the healthcare sector has continued to witness new heights. Penny stocks are grabbing attention from market participants as they are low-pr...

Australian regenerative medicine company Orthocell (ASX:OCC) has been granted a new US method of use patent for its CelGro product.

Summary World-leading regenerative medicine player Orthocell Limited has obtained US patent for CelGro®. The patent also complements market authorisation of Striate+, the first CelGro® product. CelGro® offers its benefits in the field...

Summary ASX shares have been on an upward swing on Monday. The benchmark index rose sharply since the Morning and is up nearly 1%.  Gold spot, copper, and iron ore prices were seen lower, while oil and coal prices were higher.  ASX...

The Orthocell Ltd (ASX: OCC) share price has had a mixed day of trading so far after the company announced a new United States patent for its flagship product. After tracking as high as 58 cents this morning, shares in the regenerative med...

Patents for CelGro® have previously been granted in the US, Canada, Europe, China, Japan, Singapore, Australia and New Zealand, and the new US divisional patent further protects and strengthens the IP position by providing greater layers of...

Australian regenerative medicine company Orthocell (ASX:OCC) says its 'Striate +' produce has been recommended to be added to the Australian government's Prostheses List.

Orthocell Ltd (ASX: OCC) shares are edging higher in mid-afternoon trade after the company announced it has been recommended for inclusion on the Australian Prosthesis List. At the time of writing, the Orthocell share price has risen 3.85%...

The Prosthesis list defines the minimum amount of benefit to be paid by private insurers for CelGro®product used in approved dental bone and soft tissue repair procedures.

CelGro represents a breakthrough in soft tissue reconstruction and offers commercial potential in existing addressable markets of bone, tendon, nerve and cartilage, and wider applications in general surgical and soft tissue reconstructive a...

Australian regenerative medicine company Orthocell (ASX:OCC) has announced the publication of a successful case study focused on the combination of its CelGro collagen medical device with autologous tenocyte implantation (Ortho-ATI)...

Perth-based regenerative medicines outfit Orthocell has developed a biological collage membrane device, called Celgro. And it has FDA approval. ... Read More The post Dr Boreham’s Crucible: Orthocell’s got some nerve… and FDA, TGA and CE ap...

The case study has proven that CelGro®, combined with Ortho-ATI® is effective in returning a patient to normal function and has been published in the International Journal of Case Reports.

Regenerative medicine company Orthocell (ASX:OCC) has announced it has received an R&D Tax Incentive refund of almost $2.4 million for 2019-20.

The funds will be invested into the Striate+ partnering program, progression of CelGro® nerve repair regulatory approvals, and to advance the development and commercialisation of Ortho-ATI®.

Drug development is a long and tedious process, often taking years to reach commercialisation. Small-cap biotech company Orthocell Ltd [ASX:OCC] knows this all too well, having spent years bringing their tissue repair... The post Orthocell...

Summary ASX 200 recovered after slipping in the early trade, with healthcare and technology sectors pulling the ASX chords. ASX rebound by driven by Pro Medicus (11.01per cent), Polynovo (5.2 per cent), Afterpay (7.46 per cent), and Zi...

The Orthocell Ltd (ASX: OCC) share price is one of the best performers on the market today. This comes after the company announced that it has received regulatory approval for its flagship product, CelGro. At the time of writing, the regen...

US market clearance provides a pathway for OCC to continue driving the development of CelGro collagen medical device in the key peripheral nerve repair application, and it will pursue negotiations with multi-national dental companies for ma...

US market clearance provides a pathway for OCC to continue driving the development of CelGro collagen medical device in the key peripheral nerve repair application, and it will pursue negotiations with multi-national dental companies for ma...

Summary Orthocell has received FDA 510(k) clearance to market and supply its CelGro device in the US market. It is an approved device which helps in the dental bone and tissue regeneration procedures. Managing Director of Orthocell, P...

The company recently received the green light to introduce its CelGro® collagen medical device into the Australian dental bone and tissue regeneration market.

Summary Regenerative medicine company Orthocell receives market approval for its collagen medical device, CelGro®. The Company is well-positioned to achieve approvals for production and supply of CelGro® for nerve and tendon repair. O...

The Orthocell Ltd (ASX: OCC) share price is surging higher today. This comes after the biotechnology company received Australian market approval for its CelGro product. CelGro is a collagen scaffold that supports tissue reconstruction and...

The approval positions Orthocell well for US Food and Drug Administration (FDA) approval, targeted for 2021.